GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RespireRx Pharmaceuticals Inc (OTCPK:RSPI) » Definitions » Interest Coverage

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Interest Coverage : 0 (At Loss) (As of Sep. 2023)


View and export this data going back to 2009. Start your Free Trial

What is RespireRx Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. RespireRx Pharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $-0.33 Mil. RespireRx Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $-0.07 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for RespireRx Pharmaceuticals's Interest Coverage or its related term are showing as below:


RSPI's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 131.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


RespireRx Pharmaceuticals Interest Coverage Historical Data

The historical data trend for RespireRx Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

RespireRx Pharmaceuticals Interest Coverage Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RespireRx Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RespireRx Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Interest Coverage falls into.



RespireRx Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RespireRx Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, RespireRx Pharmaceuticals's Interest Expense was $-0.60 Mil. Its Operating Income was $-1.58 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

RespireRx Pharmaceuticals did not have earnings to cover the interest expense.

RespireRx Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Here, for the three months ended in Sep. 2023, RespireRx Pharmaceuticals's Interest Expense was $-0.07 Mil. Its Operating Income was $-0.33 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

RespireRx Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


RespireRx Pharmaceuticals  (OTCPK:RSPI) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


RespireRx Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of RespireRx Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.
Executives
David Dickason officer: SVP of Pre-Clinical Prod. Dev. 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Timothy L. Jones director, officer: CEO and President 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Manuso James S J director, officer: President & CEO 5130 ROUTE 212, WILLOW NY 12495
Katie Macfarlane director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Purcell Richard David Jr. officer: SVP - Research & Deleopment 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Marc M Radin officer: Controller 33 FRANKLIN PLACE, GLEN ROCK NJ 07452
Robert N Weingarten director, officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
Aurora Capital Llc other: Member of a 10% owner group 354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167
Aurora Capital Corp other: Member of 10% owner group
Jeff Eliot Margolis director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Steven Chizzik other: Member of 10% owner group C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083
Arnold Lippa director, officer: Chairman, CEO and President, other: Member of 10% owner group C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
T. Morgen Capital Llc other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Kenneth M Cohen other: Member of 10% owner group 12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Headlines

From GuruFocus